China launches nationwide crackdown on medical insurance fraud

Int’l desk: China’s National Healthcare Security Administration (NHSA) has implemented new enforcement rules to address rising concerns over medical insurance fraud. The new regulations, titled Implementing Rules on the Supervision of the Use of Medical Insurance Funds, aim to bolster oversight and combat fraudulent practices within the healthcare sector. This announcement marks the official launch of a nationwide campaign targeting illegal activities in the medical insurance and pharmaceutical sectors.

The phase one of the crackdown is set to run through July 2026, with a strong emphasis on identifying and eliminating fraudulent practices in hospitals, clinics, pharmacies and other medical entities. According to the NHSA, the new regulations provide a more detailed framework to combat the abuse of medical insurance funds, specifying actions that would be considered fraudulent. These include the manipulation of medical records, the promotion of treatments and drugs through false advertising and the encouragement of patients to seek treatment under false identities.

The new rules explicitly prohibit the reselling of insured drugs, fabricating medical records and providing patients with improper incentives or fee waivers to induce unnecessary treatments. Institutions found guilty of these practices will face significant administrative penalties and individuals who knowingly participate in such schemes could face criminal charges.

A crucial element of the new regulations is Article 41, which mandates criminal referrals for serious violations. This article ensures that cases meeting criminal thresholds will be transferred directly to judicial bodies for prosecution, a step that is expected to strengthen accountability and serve as a deterrent to future offenders.

The crackdown primarily aims to protect China’s basic medical insurance fund, which covers approximately 95 percent of the population. The Chinese government has been under increasing pressure to ensure that public healthcare funds are used efficiently as the nation’s population ages, leading to higher demand for healthcare services. Previous efforts to combat fraud have resulted in the recovery of billions of yuan in misused funds, but the new regulatory framework aims to introduce greater operational clarity and enhance coordination across multiple government agencies.

"With this initiative, we aim to enhance the protection of healthcare funds and ensure that they are used for the benefit of our citizens," said Liang Zhao, a senior official at the NHSA. "This crackdown will target all levels of the healthcare system to prevent exploitation and safeguard the interests of the people."

The first phase of the nationwide campaign, which began on April 1, 2026, will focus on the initial identification and rectification of fraudulent activities. Authorities have vowed to conduct rigorous audits of hospitals, clinics and pharmacies, including unannounced inspections.

The second phase, slated for September to November 2026, will involve more stringent enforcement actions, including the imposition of severe fines, suspension of business licenses, and potential criminal prosecutions. Entities found to be in violation will be required to pay restitution and may face long-term bans from operating within the medical and pharmaceutical sectors.